ClinicalTrials.Veeva

Menu
F

Fox Chase Cancer Center | Philadelphia, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Paclitaxel
Pembrolizumab
Carboplatin
Cisplatin
Bevacizumab
Gemcitabine
Nivolumab
Docetaxel
paclitaxel
cisplatin

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

158 of 1089 total trials

(Peak) a Phase 3 Randomized Trial of CGT9486+Sunitinib Vs. Sunitinib in Subjects with Gastrointestinal Stromal Tumors

This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll...

Enrolling
Metastatic Cancer
Advanced Gastrointestinal Stromal Tumors
Drug: CGT9486 plus sunitinib
Drug: CGT9486

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bl...

Enrolling
Bladder Cancer
Other: Placebo
Procedure: Surgery (RC plus PLND)

This is a first-in-human, Phase 1, multicenter, open-label, dose-escalation study to establish the maximum-tolerated dose (MTD) or recommended dosage...

Active, not recruiting
HER2-expressing Cancers
Drug: ZW49

The goal of this clinical trial is to test CPO301, a type of drug called an antibody drug conjugate in adult patients with advanced or metastatic sol...

Enrolling
Cancer, Lung
Cancer
Drug: CPO301

PART 1: The primary objective of this study is to identify the maximum tolerated dose (MTD) of MK-3795, formerly called PT2385 and/or the recommended...

Active, not recruiting
Kidney Cancer
RCC
Drug: MK-3795
Drug: Nivolumab

Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors.Estimate the maximum tolerated dose...

Active, not recruiting
KRAS p.G12C Mutant Advanced Solid Tumors
Drug: Anti PD-1/L1
Drug: sotorasib

This study will enroll approximately 160 adult participants who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicab...

Active, not recruiting
Marginal Zone Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: axicabtagene ciloleucel
Drug: Cyclophosphamide

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin

This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX110 in subjects with relapsed or refractory B-cell malig...

Active, not recruiting
Adult B Cell ALL
B-cell Lymphoma
Biological: CTX110

This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25...

Active, not recruiting
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Drug: Oxaliplatin
Drug: Fluorouracil

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Active, not recruiting
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essen...

Active, not recruiting
Essential Thrombocythemia
Drug: Ropeginterferon alfa-2b-njft (P1101)

This is a First-in-Human Phase I trial of ATG-101 in Patients with Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas.

Enrolling
Advanced Solid Tumor
Mature B-cell Non-Hodgkin Lymphoma
Drug: ATG-101

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician...

Enrolling
Metastatic HER2-positive Breast Cancer
Drug: Trastuzumab
Drug: Gemcitabine

The purpose of study ANV600-001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, immunogenicity and antitumor ac...

Enrolling
Advanced Solid Tumor
Drug: ANV600
Drug: ANV600 + pembrolizumab (KEYTRUDA®)

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Emactuzumab
Drug: Niraparib

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling
Endometrial Adenocarcinoma
Urothelial Carcinoma
Diagnostic Test: OncoSignature
Drug: ACR-368

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC...

Enrolling
Renal Cell Carcinoma
Biological: Pembrolizumab
Biological: V940

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

Active, not recruiting
Desmoid Tumor
Desmoid
Other: Placebo
Drug: AL102

This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with...

Active, not recruiting
Carcinoma, Renal Cell
Drug: Cabozantinib
Drug: Atezolizumab

Trial sponsors

Temple University Health System (TUHS) logo
National Cancer Institute (NCI) logo
G
R
E
Pfizer logo
SWOG Cancer Research Network logo
Bristol-Myers Squibb (BMS) logo
ECOG-ACRIN Cancer Research Group logo
Alliance for Clinical Trials in Oncology logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems